ICH Q6B - Specifications for Biotechnological/Biological Products

What it says

Specifications for biotechnological and biological products should be established based on a combination of process consistency data, stability data and relevant development and clinical experience, selecting analytical procedures and acceptance criteria appropriate to the product's inherent heterogeneity and complexity, complementing the small-molecule specification approach in ICH Q6A.

Paraphrased for plain-language clarity. Always verify against the current published regulation text.

What it means in practice

• Because biological products are inherently more heterogeneous and complex than small-molecule drugs, this guideline recognizes that specification setting for biologics leans more heavily on accumulated manufacturing and clinical experience than a purely fixed, one-time specification exercise.
• Specifications set under this guideline are expected to evolve as manufacturing experience accumulates, meaning a specification appropriate at initial licensure may later be tightened or adjusted as more process and stability data become available.
• This guideline works closely with ICH Q5E, since demonstrating comparability after a process change ultimately depends on whether the product still meets specifications that were set with this guideline's principles in mind.

What inspectors look for

• Whether specifications in current use are supported by the process consistency and stability data cited to justify them, rather than set arbitrarily.
• Whether specification limits have been reassessed as additional manufacturing and stability experience accumulated, where that reassessment was warranted.
• Whether analytical procedures used to test against specifications are appropriate to the product's complexity and capable of reliably detecting out-of-specification material.

Related regulations